78
Participants
Start Date
March 4, 2021
Primary Completion Date
August 1, 2023
Study Completion Date
January 15, 2027
Liraglutide
"The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.~The dose will increase each week over 4 or 5 weeks until the final dose is reached."
Placebo
The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.
UZ Brussel, Brussels
UZ Leuven - Kindergeneeskunde, Leuven
Kantonsspital Olten, Olten
Kinderspital Endokrinologie, Zürich, Zurich
UBMD Peds-Div of Endo/Diabetes, Buffalo
UPMC Child Hosp-Pittsburgh, Pittsburgh
Barry J. Reiner, MD LLC, Baltimore
Rambam MC - Department of Pediatrics A, Haifa
Schneider MC - Endrocrinology and Diabetes, Petah Tikva
University of Minnesota_CPOM, Minneapolis
University Malaya Medical Centre, Lembah Pantai
Pennington Biom Res Ctr, Baton Rouge
Consultorio de Endocrinología y Pediatría, Puebla City
Children's Hospital Colorado, Denver
Solaris Clinical Research, Meridian
Mamc & Lnjp, New Delhi
FSBI 'I.I. Dedov National Medical Research Center of Endocrinology' of the MH of Russia, Moscow
Samara Regional Children Clinical Hospital n.a. N.N. Ivanova, Samara
Endolife Specialty Hospitals, Guntur
NSMU paediatric clinic, Novosibirsk
Siberian State Medical University, Tomsk
Hospital Da Luz S.A., Lisbon
Hospital da Luz, Lisbon
Centro Hospitalar Lisboa Norte, Lisbon
Unidade Local De Saude De Santa Maria E.P.E., Lisbon
Unidade Local de Saúde de Santo António, E.P.E, Porto
CUF-Porto, Porto
Hospital CUF Porto S.A., Porto
Lead Sponsor
Novo Nordisk A/S
INDUSTRY